FDA says Ozempic, Wegovy are not in short supply anymore, which could impact prices
The U.S. Food and Drug Administration said Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply. CBS News New York reporter Ali Bauman reports on whether the supply change could lead to consumers paying more.
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Weight loss drugs such as Ozempic and Wegovy are effective but may not suit everyone due to cost or side effects. Incorporating low-GI foods like avoc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback